Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Bladder intracavitary hyperthermic perfusion chemotherapy (HIPEC) is a promising treatment for non-muscular invasive bladder cancer (NMIBC). However, the molecular mechanisms underlying the response to HIPEC remain poorly understood. This study aimed to elucidate the transcriptomic profiles associated with the response to HIPEC in NMIBC patients.
Methods: RNA sequencing was performed on bladder tumor samples from NMIBC patients who underwent HIPEC treatment. Differentially expressed genes (DEGs) between responders and non-responders to HIPEC were identified. Gene ontology and pathway analysis were conducted to explore the biological functions and pathways enriched in the DEGs. Additionally, the expression of specific immune-related genes was evaluated for their association with HIPEC response. The diagnostic efficiency of selected genes in predicting relapse before and after HIPEC treatment was assessed in a validation cohort.
Results: We assessed the expression status of differentially expressed genes (DEGs) between responders and non-responders to HIPEC. Gene ontology and pathway analysis revealed that DEGs were enriched in immune-related pathways, including cytokine-cytokine receptor interaction, chemokine signaling pathway, and antigen processing and presentation. Furthermore, the expression of several immune-related genes, including ZMAP4, UPP2, and GALR1, was significantly associated with the response to HIPEC. Therefore, the immune system's reaction plays a crucial role in the response to HIPEC in patients with NMIBC. At last, a considerable diagnostic efficiency that tissue TMEFF2, KRT222, and GTSF1 in predicting relapse in NMIBC patients after HIPEC treatment, and ZMAP4, UPP2, and GALR1 in predicting relapse in NMIBC patients before HIPEC treatment in the validation cohort.
Conclusion: Transcriptomic profiling revealed that immune-related pathways and genes play a crucial role in the response to HIPEC in NMIBC patients. These findings suggest that transcriptomic profiling could provide a valuable tool for predicting treatment outcomes and identifying therapeutic targets for NMIBC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11842869 | PMC |
| http://dx.doi.org/10.1002/cam4.70672 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immune checkpoint inhibitors combined with chemotherapy in conversion therapy for stage IV gastric cancer: a multicenter retrospective cohort study.
Cancer Immunol Immunother
September 2025
Department of Gastric Surgery, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Hangzhou, 310022, Zhejiang, China.
Objectives: To evaluate the efficacy of combining PD-1 inhibitors with chemotherapy in conversion therapy for patients with stage IV gastric cancer and to determine the populations most likely to benefit from this regimen.
Methods: Data from patients with stage IV gastric cancer who received conversion therapy with PD-1 inhibitors combined with chemotherapy between January 2018 and December 2022 at multiple centers were retrospectively reviewed. Patients who underwent conversion surgery were categorized into a surgery group, while those who did not were placed into a palliative group.
Prognosis and clinical characteristics of signet ring cell colorectal peritoneal metastases - a Swedish population-based study.
Eur J Surg Oncol
September 2025
Department of Surgical Sciences, Colorectal Surgery, Uppsala University, Uppsala University Hospital, Uppsala, 751 85, Sweden.
Background: Signet ring cell (SRC) colorectal cancer is strongly associated with peritoneal metastases (PM), but the role of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) remains uncertain due to poor prognosis. This study aimed to analyse the prognostic impact of SRCs, assess clinical characteristics, and evaluate the risk of open-close laparotomy.
Methods: This Swedish population-based study included patients with colorectal PM accepted for initial CRS and HIPEC at four national centres between 2010 and 2023.
Response to Comments Regarding "Survival Outcomes of Cytoreductive Surgery with HIPEC in Gastric Adenocarcinoma: A National Cancer Database Study" by Vasigh et al.
Ann Surg Oncol
September 2025
Division of Surgical Oncology, Department of Surgery, University of Colorado School of Medicine, Aurora, CO, USA.
Emerging treatment modalities for gastric cancer with peritoneal metastases: A systematic review.
Oncologist
August 2025
Department of Oncology, Catharina Cancer Institute, Catharina Hospital, Michelangelolaan 2, 5623 EJ, Eindhoven, the Netherlands.
Introduction: Gastric cancer remains associated with a high mortality, since patients often present with advanced-stage disease such as peritoneal metastases. Treatment options in this setting are limited and mainly consist of palliative systemic therapy.
Objectives: This systematic review aims to summarize emerging therapeutic strategies for patients with peritoneally metastasized gastric cancer in relation to response, toxicity and survival.
Tumor Microenvironment-Responsive Nanocluster for Time-Resolved Hyperthermic Intraperitoneal Chemo/Thermal-Therapy against Colorectal Peritoneal Metastasis.
ACS Appl Bio Mater
August 2025
Departments of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Peritoneal metastasis (PM) originating from gastrointestinal cancer was considered a terminal disease until recently. It poses significant therapeutic challenges due to its diffuse nature and barriers to effective drug delivery. While locoregional approaches such as hyperthermic intraperitoneal chemotherapy (HIPEC) extend survival, their efficacy is constrained by systemic toxicity and tumor thermoresistance.
View Article and Find Full Text PDF